Blog Lasmi19: CURAIZON = Target countries with national health services.

National health services play an important role in increasing, extending and saving lives. In many areas, including cancer, asthma and diabetes, they have increased dramatically ...

ABOUT

We solve real-world problems by helping patients take their drugs correctly

Every day, millions of people fail to take their medicine as determined and the personal and financial costs generated are shocking. Around the world, non-compliance generates $ 700 billion in medical costs that can be avoided.
The data we make is unique and has tremendous value for pharmaceutical companies, researchers, and the government.
Every time a patient uses our CuraServe technology, our data grows in utility and value.
Curaizon ™ solves the problem of drug disobedience by deploying our technology through national health services. As part of our solution, we collect full anonymous data about how and when patients use drugs.
CuraTokens ™ is the only way to access our data. Tokens can be exchanged for data access, which will advance medical research, reduce health care costs and save lives.
CuraToken ™ values are based on real solutions to real problems.

Play videos and learn more about Curaizon ™

What does the company do?

We aim to improve drug adherence and bring benefits that transform games for patients and healthcare providers by becoming a major supplier of data compliance and solutions throughout the world.

What is unique about the company?

Our solutions work with patients, their families and health care providers to ensure that patients take their medicine as determined through a series of outreach tools, supported by predictive modeling tools and behavioral analysis, to improve drug adherence.

What problems did the company solve?

Our CuraServe technology helps ensure that patients take their medicine as determined by their doctor. By doing this, we help patients live longer and healthier. We also reduce health care costs that occur when patients fail to take their medication properly.

How do you create value to support your CuraTokens?

Our CuraServe ™ technology produces a large number of unique and real-time data that shows how people use their most valuable drugs for various groups including pharmaceutical companies, medical researchers, and biotechnology companies. CuraTokens ™ allows owners of tokens to access data to make queries. When our solution is launched to more patients in more countries. The more data we produce, the more valuable that CuraTokens ™ becomes.

Who is your target customer?

Curaizon ™ sells its compliance solutions (CuraServe ™) to national health services worldwide. Our end users are health care patients who take any form of medicine. We also work with industry, pharmaceutical and biotechnology academics, as well as other data users through our CuraData ™ solution.

What is your geographic market target?

Curaizon targets countries with national health services. Currently it covers 1.4 billion people and that number continues to grow.

What is the market potential?

Global non-compliance costs are more than € 600 billion every year and generate hundreds of thousands of lives lost prematurely. Compliance with chronic and long-term diseases is less than 50%.

Curaizon ™ ecosystem

CuraToken ™ Utility Tokens (CTKN) allows token holders to access our exclusive and anonymous medical data on blockchain.

CuraTokens ™ is the only way to access Curaizon ™ technology.
CuraToken ™ holders can access data that uses strong analytics, predictions, AI and big data in the fight against drug non-compliance.
CuraTokens ™ provides a real-time analysis of patient behavior and compliance.
CuraTokens ™ enables the use of blockchain technology to manage authentication, confidentiality and accountability by allowing individuals to control their data, provide protection, security, and compliance with all necessary regulations, including GDPR.
CuraTokens ™ facilitates partnerships with medical and pharmaceutical organizations through the token reward system.
CuraToken ™ holders know that they are saving lives around the world by helping solve the problem of drug non-compliance.

January 2016

Development of CuraServe ™ Start

June 2017

CuraServe ™ testing takes place

February 2018

Rilis Full Alpha CuraData ™

June 1, 2018

Start Token Presale

June 8 2018

Token Public Sales Start

November 2018

Beta Release CuraData ™ Complete

March 2019

CuraServe ™ Public Release

July 2019

CuraData ™ Platform Growth

2020

Release of Curadata ™ 2.0

Our team combines passion, innovation and expertise with experience in the fields of health, finance, operations, marketing and technology

LEADERSHIP

Nicholas James Rumble

Chief Executive Officer (CEO)

Nicholas has a background in mathematics and economics and spends most of his work in investment banking. He was recently responsible for the operations of Asia Pacific and Australasia owned by Saxo Bank. He is very involved in retail and institutional client relationships and plays a role in pioneering new trading technologies. He brings more than 20 years of business experience and knows how to bring great teams together and implement high-level plans; especially where technology plays a key role.

Chris Matey

Chief Operations Officer (COO)

Chris has an MBA in finance and JD. He has experience as a financial analyst, director and executive as well as experience in startup and technology companies and an entrepreneur. In his roles in OrderTrust ™ and CyberCash ™, he developed high-volume payment-related products used worldwide. In his work as a consultant he has worked with various companies around the world that provide strategic analysis and fundraising support.

Mark Nathan

Chief Financial Officer (CFO)

Mark Nathan is a registered accountant who has worked with Curaizon since 2015. He has high-level experience in business operations in various sectors. This system compares performance and costs with budget / estimates and extracts volume / mix variations in relation to revenue models to assess the 'top-line' profitability has been deployed several times. Mark's focus is to help the growth and development of a stable company, with the slope of controlling costs throughout the business, through the annual budgeting process, and the program predicts every three months.

Darran Trute

Chief Technology Officer (CTO)

Darran has sent various IT solutions to clients ranging from blue chip companies to not getting profit. He currently specializes in blockchain-related projects that provide technical expertise to deal with real-world problems. Darran also has extensive experience in redesigning the pioneering health sector to meet the huge demands of an aging population with complex health needs.

Luke Lerdal

Chief Data Officer (CDO)

Lukas has a broad background in modeling and data systems. He has led a complex data analysis project with an emphasis on big data. His responsibilities include overseeing data integration and CuraServe ™ and CuraData ™ data structures.

BUSINESS DEVELOPMENT

Andrey Verbitsky

Tokenomika Expert

Andrey has designed more than 80 tokens and is widely regarded as a leading expert in crypto economics and currency. He has consulted in various industries, advising on ICO application strategies and blockchain to drive business impact and bring value to investors, founders and end users.

He brings exceptional experience and expertise in the fields of technology, economics and behavioral science with more than 20 years of experience in the field of telecommunications, product management and consulting, working with many Level 1 clients throughout the world.

Pencho Gavazov

Director of Business Development

Pencho has a background in innovation and entrepreneurship. His experience as a marketing manager and business development consultant has placed him in an international business environment. A large amount of his work experience is in the health sector where he has been successful in market acquisition activities by expanding sales on four continents. One of his main achievements was in strategic development where he successfully built a co-branding partnership with Tracoe, the world's leading medical equipment manufacturer in the field of tracheotomy. Pencho has worked with Curaizon ™ since it began in 2015.

Kristaps Kuhalskis

Creative director

Kristaps has a master's in international business and innovation and entrepreneurship and an advanced degree in multimedia design & communication. He has work experience in global branding strategies, marketing and communication and execution, project management, multimedia development and human resources. His experience includes working in leading global market research companies, industrial manufacturing, technology start-ups, and his own creative agency. Kristaps's creative mindset, coupled with its ability to work in various countries and cultural environments, is a great asset for the team.

ADVISOR

Dr. Rory McCrea

MB BS, MSc, MRCGP

Rory has been explained by the Financial Times in the UK as a "Health Entrepreneur". He gained this reputation for far-reaching innovation as Chair of ChilversMcCrea Healthcare, which was founded and supervised, from startups in 2001 to successful transfers in 2010 to Trade Partners, a network of more than 40 General NHS Practices and Urgent Care services throughout the UK and Wales. Rory is also very influential in the public sector who has been Medical Director with NHS West Essex for more than a decade before becoming Director of Clinical Transformation with the Essex West Clinical Commitment Group. Rory will be the driving force behind the application of Curaizon ™ technology in various national health care services. Rory has been a member of Curaizon's advisory board since 2015.

Sarah Chilvers

BSc, RGN, RHV, MBA, DProf

Sarah has spent her life working at, and with, the British National Health Service. First as a registered nurse and health visitor and then in NHS management. Sarah went on to complete her Professional Doctorate degree at Middlesex University in 2004, specializing in new ways of providing health services and has worked to encourage innovation and clinical excellence for more than 25 years. Winner of the 2008 Laing and Buisson Independent Health Award for Entrepreneurship Achievement, Sarah has a perfect blend of clinical and business experience that has proven invaluable in her advisory role in Curaizon ™ since 2015. She is responsible for integrating our clinical trials and adoption. our technology in various national health services.

Parexel

Biopharmaceutical service providers

Parexel International is a global biopharmaceutical service provider. It conducts clinical trials on behalf of its clients to expedite the approval process. This is the second largest clinical research organization in the world and has helped develop around 95% of the 200 best-selling biopharmaceuticals on the market today. Parexel is our clinical testing partner in the UK and will provide liaison studies to enter each new region.

CEO Curaizon explains what we do